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Abstract: Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous 
system characterized by chronic inflammation, demyelination, and axonal damage. As 
microRNA (miRNA)-dependent alterations in gene expression in hematopoietic cells are 
critical for mounting an appropriate immune response, miRNA deregulation may   
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result in defects in immune tolerance. In this frame, we sought to explore the possible 
involvement of miRNAs in MS pathogenesis by monitoring the differential expression of 
22 immunity-related miRNAs in peripheral blood mononuclear cells of MS patients and 
healthy controls, by using a microbead-based technology. Three miRNAs resulted >2 folds 
up-regulated in MS vs controls, whereas none resulted down-regulated. Interestingly, the 
most up-regulated miRNA (mir-155; fold change = 3.30; P = 0.013) was previously 
reported to be up-regulated also in MS brain lesions. Mir-155 up-regulation was confirmed 
by qPCR experiments. The role of mir-155 in MS susceptibility was also investigated by 
genotyping four single nucleotide polymorphisms (SNPs) mapping in the mir-155 genomic 
region. A haplotype of three SNPs, corresponding to a 12-kb region encompassing the  
last exon of BIC (the B-cell Integration Cluster non-coding RNA, from which mir-155  
is processed), resulted associated with the disease status (P = 0.035; OR = 1.36,   
95% CI = 1.05–1.77), suggesting that this locus strongly deserves further investigations. 
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1. Introduction 
Multiple sclerosis (MS) (OMIM #126200) is a common autoimmune disease of the central nervous 
system (CNS) characterized by chronic inflammation, myelin loss, varying degrees of axonal 
pathology, and progressive neurological dysfunction [1–3]. According to the presentation and severity 
of symptoms, MS subtypes are generally classified as relapsing remitting (RR; the commonest form), 
primary progressive (PP), or secondary progressive (SP) [2]. 
The causes of MS are still largely to be discovered; however, as with many common diseases, it is 
clear that both genetic and environmental components play a role [4]. Over the past decade a number 
of genetic studies have been attempted to map susceptibility loci for MS. These include candidate gene 
studies, linkage analysis, association analysis, and, more recently, genome-wide association studies 
(GWAS) [5–12]. To date, the human leukocyte antigen (HLA) gene cluster on chromosome 6p21.3 
remains the strongest and most convincing susceptibility locus both linked to, and associated with,  
MS [13]. As for non-HLA loci, GWAS have substantially contributed to identify a number of MS 
susceptibility genes: so far, approximately 50 genes conferring a mild-to-modest effect on risk (odds 
ratio, OR < 1.3) have been robustly associated with MS, many of which display primarily 
immunologic functions [9,12,14]. 
Despite these extensive studies, identification of MS-specific genes still remains challenging and 
mainly focused on protein-coding loci. MicroRNAs (miRNAs) are a class of short (~22 nucleotides) 
single-stranded non-coding RNAs that modulate the expression of multiple target mRNAs by inducing 
either translational repression or mRNA degradation. MiRNAs have emerged as key post-transcriptional 
regulators of diverse biological processes, and mounting evidence point to miRNAs as critical players 
not only for the development of the immune system, but also for the correct function of both its innate 
and adaptive branches [15,16]. In particular, to maintain tolerance, central and peripheral lymphoid 
organs present different checkpoints: these ensure that auto-reactive T and B cells, which are routinely Int. J. Mol. Sci. 2011, 12 8697 
 
and randomly generated during lymphogenesis, are deleted or silenced [17,18]. However, self-reactive 
lymphocytes can escape the checkpoints, survive in peripheral lymphoid tissues, and, once activated, 
attack self-tissues. Considering that miRNAs are stringently regulated in immune cells to maintain 
immune homoeostasis, it is conceivable that dysregulation of miRNA expression levels can determine 
an immune-tolerance breakdown and, therefore, the development of autoimmunity. Indeed, several 
studies have revealed that various miRNAs are dysregulated in autoimmune disorders, such as 
systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) [16]. 
Concerning MS, nine miRNA expression studies have been reported so far [19–29]. These studies 
were principally performed by comparing miRNA expression profiles in MS cases and controls in a 
variety of tissues: whole blood, peripheral blood mononuclear cells (PBMCs), serum, MS lesions, as 
well as sorted B, CD4+, and CD8+ lymphocyte sub-populations. In particular, two studies addressed 
miRNA expression in PBMCs, and both found significant dysregulation of specific miRNAs in the  
MS relapse phase compared to controls [23,29]. In one case, three out of 364 miRNAs (i.e., mir-18b, 
mir-493, and mir-599) were significantly upregulated [23], whereas in the other study, which was 
focused only on 5 immune-related miRNAs, mir-21, mir-146a, and mir-146b were significantly 
overexpressed [29]. However, specific and reproducible miRNA signatures associated with MS are 
still lacking. 
In the present study, we investigated the possible involvement of 22 immunity-related miRNAs in 
MS by monitoring their differential expression in PBMCs of RR MS patients and healthy controls. 
Genetic association with MS was also explored for the most up-regulated miRNA gene, mir-155. 
2. Results and Discussion 
2.1. miRNA Selection 
To be relevant for the molecular pathogenesis of MS, candidate miRNAs would be expected either 
to be pivotal players in activation/function of immune responses, or to be expressed in tissues affected 
by the disease process (e.g., brain), or to map within regions that have been linked/associated with MS. 
Accordingly, we selected 22 immunity-related miRNAs (Table 1) based on the following criteria: 
(i)  human miRNAs expressed in the immune system and showing immune-related functions were 
retrieved from the literature [30–43]; 
(ii)  human miRNA genes mapping within loci previously associated with MS or EAE 
(experimental autoimmune encephalitis, the experimentally-induced form of MS in animal 
models) were extracted using the UCSC genome browser (reference sequence NCBI Build 
36.1/hg18), crossing data extracted with the sno/miRNA track with those extracted either with 
the GAD View or with the RGD-Rat-QTL/ MGI-Mouse-QTL tracks; 
(iii) miRNAs known to be preferentially expressed in tissues/cells involved in MS were retrieved 
from the literature, as well as through publicly available miRNA expression repositories   
(i.e., the smiRNAdb database and the miRNA Map website [44]). 
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Table 1. MiRNAs selected for expression profiling by the Luminex Microbead miRNA Profiling system. 
  miRNA  Genomic 
location 
1  Expression 
2  Known targets 
2, 
3  Function 
2  Association 
1 
MS EAE 
1  let-7f  chr9q22 
chrXp11  CD8+ T cells (ubiquitous)  TLR4  innate immune response 
no 
yes 
2  mir-15a  chr13q14 thymus,  spleen  DMP1/DMTF1  unknown 
no 
3  mir-15b  3q26 
CD8+ T cells, lymphocyte development 
no validated targets 
mutations in mir16–15 cause autoimmune and B 
lymphoproliferative disease in mice  4  mir-16  chr3q26 
chr13q14  BCL2, TPPP3 
5  mir-17-3p  chr13q31 lymphocytes,  lymphoid  tissues  PTEN, Bim, AML1  mir-17–92 cluster higher expression in lymphocytes 
causes autoimmune disease in mice 
6  mir-17-5p  chr13q32 myeloid  cells  no validated targets 
mir-17–92 cluster higher expression in lymphocytes 
causes autoimmune disease in mice; monocyte 
proliferation and differentiation 
7  mir-18a  chr13q31  placenta, spleen, kidney, thymus  no validated targets 
mir-17–92 cluster higher expression in lymphocytes 
causes autoimmune disease in mice 
8  mir-19a  chr13q31 
chrXq26  lymphocytes, lymphoid tissues PTEN,  Bim 
9  mir-19b-1 
chr13q31 
thymus, ovary, prostate, spleen  no validated targets 
10  mir-20a  lymphocyte development; bladder, lung, 
thymus  AML1 
11  mir-21  chr17q23  CD8+ T cells, lymphocyte development  PTEN, Pdcd4, TPM1, IL12a  macrophage activation  no 
4 
12  mir-23b  chr9q22 
hematopoietic cells  Notch1 neural  development 
no 
yes 
13  mir-27b  lung, UBC-EPC, MVEC, CTCL  CYP1B1, Notch1  neural development 
14  mir-92a  chr13q31 
Xq26  lymphocytes, lymphoid tissues PTEN,  Bim  mir-17–92 cluster higher expression in lymphocytes 
causes autoimmune disease in mice 
no  15  mir-105  Xq28  nervous and reproductive system no  validated  targets  unknown  yes 
16  mir-142-3p  chr17q22  CD8+ T cells, lymphocyte development no  validated  targets  unknown  no 
4 
17  mir-142-5p 
18  mir-146a  chr5q33  B cells, monocytes  IRF7, TRAF6, IRAK1, IRAK2  innate immune response, induced by EBV, TLR 
signaling 
no 
yes 
19  mir-150  chr19q13  CD8+ T cells, spleen, thymus, lymphocyte 
development  Myb, AID, BACH1, CEBPB, CSFR  B-cell development, T-cell activation , innate and 
adaptive immune response 
no 
20  mir-155  chr21q21  B, T, and dendritic cells, monocytes, spleen, 
thymus, lung  
MAF, AGTR1, FADD, IKK, JARID2, 
PU.1, Ripk1, SOCS1, TAB2, CD47 
macrophages germinal center response, IgG class 
switch, peripheral T-cell development 
21  mir-181a  chr1q32.1 
chr9q33.3  
lymphocyte maturation (highest in 
CD4+CD8+ T cells) 
SHP2, PTPN22, AID, DUSP5-6, CD69, 
BCL2, TCR alpha 
lymphocyte maturation, both positive and negative 
selection  yes yes 
22  mir-181b  brain, thymus, lymphocytes  Tcl1, AID  B-cell class switch 
1 Chromosomal position according to NCBI Build 36.1/hg18 (March 2006); 
2 as retrieved from the literature and through publicly available repositories (smiRNAdb, the 
miRNA MAP website); 
3 GeneCards nomenclature is used for gene names; 
4 associated with rheumatoid arthritis. MS = multiple sclerosis, EAE = experimental 
autoimmune encephalitis. Int. J. Mol. Sci. 2011, 12 8699 
 
 
2.2. Mir-155: An MS Signature? 
MiRNA expression profiling was performed on RNA extracted from PBMCs of 10 MS cases and 
an equal number of age- and sex-matched controls, using locked nucleic acid (LNA)-modified probes 
in a liquid-phase bead-based array. Although other tissues and cell types, such as MS brain lesions or 
specific immunologic cell populations, might be more directly connected to MS pathogenic changes, 
we chose to investigate miRNA expression patterns in PBMCs, which are readily accessible and could 
potentially represent an optimal clinical sample for biomarker detection. 
After normalization, four RNA samples (all control subjects) were excluded from further analyses 
because of abnormally high/low background bead signals. Moreover, mir-18a and mir-105 did not 
show appreciable expression signals in all of the PBMC samples, and were not further analyzed. 
Monitoring for differences in expression levels between cases and controls showed a significant   
up-regulation of four miRNAs: mir-155, mir-92a, let-7f, and mir-19a (P < 0.05) (Figure 1(A)). The 
fold change was comprised between 3.3 (top hit: mir-155, P = 0.013) and 1.2 (let-7f, P = 0.0026). No 
down-regulated miRNAs were observed. 
To validate the most striking result obtained from miRNA profiling, the mature mir-155 and its 
long non-coding RNA precursor (i.e., the mir-155 host gene MIR155HG, also known as BIC, B-cell 
integration cluster) were quantitated by semi-quantitative reverse transcription-PCR (qRT-PCR).   
Real-time experiments were performed on RNA extracted from all of the 20 available subjects 
(including the four RNAs that failed the microbead-based screening). 
As expected, both transcripts resulted up-regulated in MS cases, and the difference in expression 
levels between the two analyzed groups was significant (P = 0.012) or close to significance (P = 0.053) 
in the case of BIC and mir-155, respectively (Figure 1(B)). However, fold changes were not as   
marked as those observed in microbead-based experiments, being on average mir-155 1.43-fold and  
BIC 2.12-fold more expressed in cases compared to controls. 
Even though differences in expression levels in cases vs. controls were not highly significant, in our 
opinion the identified miRNA-signature warrants further investigation. In fact, this represents the first 
case of a specific miRNA dysregulation in MS that has been replicated in two independent studies (this 
work and [21]) and in different clinical samples: actually, previous studies showed that mir-155   
is strongly up-regulated (about 12 fold) also in active MS lesions compared to normal brain white 
matter [21]. The aberrant expression of mir-155 in PBMCs of our MS patients could, to some extent, 
reflect the corresponding alterations in the brain. Interestingly, an up-regulation of mir-155 was 
reported also in CD4+ cells from the spleen, lymph nodes, and CNS of EAE mice [45], strengthening 
the hypothesis of mir-155 overexpression as an MS signature, and suggesting a possible correlation 
with disease severity and CNS infiltration of autoimmune cells. It should be noted that a very recent 
study by Fenoglio and colleagues [29] did not evidence a significant dysregulation of mir-155 in MS 
cases compared to controls. However, this difference might be due to the study design, as only RR 
patients in the relapse phase were analyzed [29], whereas we chose to focus only on the remission 
phase, to avoid the possible confounding effect of the ongoing inflammation, whose amount is 
different during the diverse phases of the disease [3]. Therefore, it would be important in the future to 
evaluate mir-155 expression in larger MS population samples, to assess its reliability as peripheral 
biomarker for the disease and/or its progression. Int. J. Mol. Sci. 2011, 12 8700 
 
 
Figure 1. Immune-related miRNA expression pattern in MS patients and healthy subjects. 
(A) miRNA analysis was performed on total RNA isolated from PBMC samples from 10 
MS patients and 6 healthy donors. The heatmap was generated using the dChip software 
after supervised hierarchical clustering analysis of all unfiltered data. Fold change (FC) is 
indicated only for those miRNAs showing significant differences in expression levels 
between cases and controls (P < 0.05; t test for comparing the 2 groups). Differential 
expression of miRNA patterns is shown by the intensity of red (up-regulation) versus blue 
(down-regulation); (B) Semi-quantitative real-time RT-PCR analysis of mir-155 and its 
precursor (BIC) in 10 MS patients and 10 controls. Mir-155 levels were normalized by the 
endogenous control mir-146a, whereas, for BIC transcripts, the hydroxymethylbilane 
synthase (HMBS) and beta-actin (ACTB) housekeeping-gene levels were used as 
calibrators. Results are presented as normalized rescaled values (calculated by the GeNorm 
software). Significance levels in differences between cases and controls are presented in 
parenthesis, and were calculated by a one-tailed t test statistics. 
 
Apart from MS, mir-155 was repeatedly reported as up-regulated in other autoimmune disorders, 
such as RA, SLE, and ulcerative colitis (UC), suggesting shared pathogenic mechanisms with MS. In 
particular, mir-155 was shown to be over-expressed in: (i) synovial tissue and fluids, as well as synovial 
fibroblasts and PBMCs of RA patients [46,47]; (ii) inflamed colonic mucosa of UC patients [48]; and 
(iii) splenic B and T cells, as well as T-reg cells in the standard induced mouse model of SLE   Int. J. Mol. Sci. 2011, 12 8701 
 
 
(i.e., collagen-induced arthritis mice, CIA) [49,50]. Notably, knock-out mice for mir-155 (mir-155
−/−) 
not only did not develop CIA, but also resulted highly resistant to EAE [51]. 
Unquestionably, both adaptive and innate immune responses are highly regulated, and mir-155 
represents a key modulator in the development, maturation, maintenance, and function of different 
immune-competent cells, like Th1, Th2, B, dendritic, and T-reg cells (Figure 2) [43]. In addition, 
several pieces of evidence indicate that mir-155 act as a positive regulator of autoimmune 
inflammation in EAE, by favoring the emergence of Th1 and Th17 cells and the consequent 
production of proinflammatory cytokines [45,52]. Hence, mir-155 might also represent a promising 
therapeutic target for MS, as suggested by the reduced clinical severity of EAE after anti-mir-155 
treatment [45]. 
Figure 2. Role of mir-155 in the regulation of adaptive/innate immunity. The figure 
depicts stages in the adaptive (upper part) and innate (lower part) immune responses in 
which the specific role of mir-155 was demonstrated. HSC, hematopoietic stem cells; CLP, 
common lymphocyte progenitor; CMP, common myeloid progenitor; MDP, myeloid 
dendritic progenitor; GMP, granulocyte monocytic progenitor; T-reg, regulatory T cell; 
Th1, type 1 T helper cell; Th2, type 2 T helper cell; Th17, type 17 T helper cell. 
 
2.3. Association Analysis with the Mir-155 Locus 
As mir-155 levels are significantly altered in MS patients, we next asked if genetic variations   
within the BIC/mir-155 gene might predispose to MS. Indeed, expression studies are often 
strengthened by the support of genetic analyses, even those showing genome-wide significant 
association signals, as in the case of the ILR2A gene [9,14]. Concerning the mir-155 locus, no 
association data were available so far. Indeed, surfing the dbGaP database, we found four single 
nucleotide polymorphisms (SNPs), located in close proximity of the BIC/mir-155 gene, and covering a Int. J. Mol. Sci. 2011, 12 8702 
 
 
genomic region of 19 kb (Figure 3), which were nominally associated (p < 0.05) with MS in 
previously performed GWAS. We therefore attempted to replicate these associations in our   
case-control Italian MS cohort of 360 cases and 662 controls. 
Figure 3. LD haplotype structure of the mir-155 locus. The structure of the genomic region 
surrounding the mir-155 gene and its precursor MIR155HG (BIC) is shown in the upper 
part of the figure; exons are represented by boxes, introns by lines, and are drawn to scale 
(RMPL39 corresponds to the mitochondrial ribosomal protein L39 gene, downstream of 
the mir-155 locus). Arrows above genes indicate their transcriptional direction. The 
genomic size is indicated by the ruler at the top of the scheme; the genomic position is 
depicted on the chromosome 21 ideogram. In the central part of the figure, genotyped 
SNPs are listed, and their genomic locations are shown by arrows. The identified risk 
haplotype is indicated with letters (referring to SNP alleles contributing to the haplotype). 
The haplotype was constructed and phased with PLINK; only phased haplotypes with 
posterior probability of 1 were included for determining OR and 95% CI (grouping 
together all the other alleles). In the lower part of the figure, the LD structure of the   
mir-155 locus is shown. Pair-wise LD values, estimated for the genotyped SNPs, are 
represented by boxes. The standard color scheme (D’/LOD) of Haploview was used to 
display the strength of LD: red indicates strong LD, pink intermediate. 
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Polymorphisms were genotyped by high-resolution melting (HRM) analysis; the mean genotyping 
success rate was 95.2% and the accuracy was >99%, according to random duplicated genotyping of 
5% of samples. Moreover, 10% of samples were analyzed using also a second technique (i.e., Sanger 
sequencing), a step introduced for genotyping quality control. None of the polymorphic loci showed a 
significant deviation from Hardy-Weinberg equilibrium (HWE). 
All of the four SNPs were analyzed using the PLINK program: allele and genotype frequencies 
between MS patients and controls were compared, but no statistically significant associations were 
found (Tables 2 and 3). However, SNP rs2829806 showed a weak trend toward significance, both in 
the allelic association (P = 0.076) and under a dominant mode of inheritance (P = 0.055; data   
not shown). 
Table 2. Allele frequency distributions in MS cases and controls. 
SNP 
Minor 
allele 
Minor allele 
frequency in MS 
cases (%) 
Minor allele 
frequency in 
controls (%) 
P value OR  95% CI 
rs1893650 T  29.4  28.1  0.53  1.07  0.86–1.32 
rs2829803 G  26.9  24.0  0.15 1.17  0.94–1.44 
rs2282471 T  16.6  14.6  0.28 1.16  0.89–1.51 
rs2829806 T  28.1  24.4  0.076  1.22  0.98–1.52 
OR: odds ratio; CI: confidence interval. 
Table 3. Genotype frequency distributions in MS cases and controls. 
SNP 
Minor 
allele 
Major 
allele 
Genotype 
frequencies in 
MS cases (%) 
Genotype 
frequencies in 
controls (%) 
P value 
rs1893650 T  C  7.5/44.0/48.5  8.9/38.4/52.7  0.24 
rs2829803 G  A  7.2/39.5/53.3  6.5/35.1/58.4  0.30 
rs2282471 T  C  2.0/29.2/68.8  3.1/23.1/73.8  0.099 
rs2829806 T  G  6.1/44.2/49.7  5.1/38.5/56.4  0.16 
To facilitate the analysis of allelic haplotypes, the level of linkage disequilibrium (LD) among the 
four SNPs was evaluated using the Haploview program. We observed a unique haplotype block, with 
the three downstream SNPs showing a lower degree of LD among each other (Figure 3). Hence, 
haplotype analysis was accomplished using a “sliding window” option, considering three adjacent 
SNPs across the region at a time (Table 4). 
The haplotype GTT, composed of SNPs rs2829803, rs2282471, and rs2829806, was over-represented 
in MS cases (13.5%) compared to controls (10.3%), thus resulting associated with the disease status  
(P = 0.035). This haplotype confers a 1.36-fold increased genetic risk of developing MS [95% 
confidence interval (CI) = 1.05–1.77] (Table 4 and Figure 3), again supporting the role of mir-155 in the 
pathogenesis of MS. Notably, other two haplotypes, determined by the same polymorphisms and both 
showing a protective effect, also resulted significantly associated with the disease (GTG, P = 0.016; 
GCG, P = 0.039). However, these haplotypes are quite rare in the analyzed population (Table 4). Int. J. Mol. Sci. 2011, 12 8704 
 
 
Table 4. Haplotype frequency distributions in MS cases and controls. 
SNPs Haplotype 
Haplotype 
frequency in 
MS cases (%) 
Haplotype 
frequency in 
controls (%) 
P value 
rs1893650 
rs2829803 
rs2282471 
TGT 13.4  11.7  0.28 
TAT 2.4  2.3  0.99 
TGC 10.9  11.4  0.70 
CGC 1.1  1.3  0.70 
TAC 3.3  2.8  0.55 
CAC 68.9  70.4  0.51 
rs2829803 
rs2282471 
rs2829806 
GTT  13.5 10.3  0.035 
ATT 2.3  2.4  0.88 
GCT 10.6  9.7  0.52 
ACT 2.3  2.0  0.61 
GTG  0.3 1.6  0.016 
GCG  1.4 2.9  0.039 
ACG 69.5  71.2  0.46 
Significant associations (p value < 0.05) are in bold characters. 
Taken together, these results suggest that the mir-155 locus can be genetically associated with MS. 
Although the precise mir-155/BIC variants responsible for the association and their functional effect 
are still unknown, one might speculate that polymorphisms affecting the expression of this miRNA 
might directly contribute to MS susceptibility. 
3. Experimental Section 
This study was approved by local Ethical Committees and was performed according to the 
Declaration of Helsinki and to the Italian legislation on sensible data recording. All recruited subjects 
signed an informed consent to participate to the study. 
3.1. Subjects 
PBMCs were collected from 10 RR MS patients, all in the remission phase, and 10 healthy subjects. 
Of the 10 patients (mean age 36.9 years; range 24–50; SD ± 10.1), six were females and four males. 
The choice to focus on the RR subtype of the disease comes from the notion that in RR-MS patients 
inflammatory events seem to have a major role, whereas, in PP-MS cases, neurodegeneration is likely 
prominent [53,54]. Controls were matched with cases in terms of gender and age (mean age 33.9 years; 
range 25–48; SD ± 7.3). 
All patients had not received any immunomodulatory therapy within three months prior to blood 
withdrawal. Moreover, to avoid possible confounder effects due to diurnal variation in immune 
function, all samples were collected between 8–11 am. Int. J. Mol. Sci. 2011, 12 8705 
 
 
3.2. RNA Samples 
PBMCs were isolated from heparinized blood by centrifugation on a Lympholyte Cell separation 
media (Cederlane Laboratories Limited, Hornby, Ontario, Canada) gradient. All blood samples were 
processed immediately after phlebotomy. Total RNA was isolated using the Eurozol kit (Euroclone, 
Wetherby, UK). 
RNA concentration was determined using the NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies, Wilmington, DE, USA). RNA quality was assessed on an Agilent Bioanalyzer 2100 
using the Agilent RNA 6000 Nano Assay kit (Agilent Technologies, Santa Clara, CA, USA). 
3.3. MiRNA Expression Profiling By Microbead-Based Technology 
Expression profiling of 22 candidate miRNAs (Table 1) was carried out by using the liquid-phase 
Luminex Microbead miRNA Profiling system with a custom FlexmiR Select miRNA Assay (Luminex, 
Austin, TX, USA). Briefly, 1 µg of total RNA was biotin labeled with the FlexmiR miRNA Labeling 
kit (Luminex), which labels all RNA molecules, including small RNAs, by first removing the   
5′-phosphates from the terminal end of the miRNAs by a Calf Intestinal Phosphatase (CIP) treatment, 
and then enzymatically attaching a biotin label to the 3′-end of the miRNAs in the total RNA sample. 
Treated RNA samples were then hybridized to beads containing different fluorophores and coated with 
LNA-modified capture probes (a different fluorophore and a single probe for each bead) complementary 
to the selected miRNAs. After washing away the unbound RNA, streptavidin-phycoerythrin (SAPE) 
reporter molecules were added to the reaction and then the expression of miRNAs was analyzed on a 
Luminex analyzer (Luminex). 
Normalization of samples and calculation of median fluorescence intensity was performed 
according to the Luminex protocol. 
The expression patterns of unfiltered data were determined using supervised hierarchical clustering 
of samples, using the DNA-Chip Analyzer software (dChip) [55]. To further define miRNAs 
differentially expressed between groups (patients vs controls), the data were filtered on significance of 
differences using the t test (P < 0.05). 
3.4. Real-Time qRT-PCR Analyses 
Stem-loop qRT-PCR for mature mir-155 (TaqMan microRNA Assay ID 002623; Applied 
Biosystems, Foster City, CA, USA) was performed according to the manufacturer-recommended 
protocols: 300 ng of total RNA were reverse transcribed in a 20-μL reaction volume, using the 
ImProm-II Reverse Transcriptase (Promega, Madison, WI, USA); 0.8 μL of the RT reaction were used 
for subsequent real-time PCRs. Data were normalized to mir-146a (TaqMan microRNA Assay   
ID 000468) levels, a miRNA that was shown, by our microbead-based profiling experiments, to be 
readily detectable and not affected by the analyzed conditions. 
Real-time qRT-PCRs for the quantitation of the mir-155 host gene were carried out using the 
FastStart SYBR Green Master Mix (Roche Applied Science, Indianapolis, IN, USA). In this case, 
random nonamers and the SuperScript-III reverse transcriptase (Invitrogen Life Technologies, 
Carlsbad, CA, USA) were used to perform first-strand complementary DNA (cDNA) synthesis, Int. J. Mol. Sci. 2011, 12 8706 
 
 
starting from 500 ng of total RNA, according to the manufacturer’s instructions. Of a total of 20 µL of 
RT reaction, 1 µL was used as template for PCR amplifications with gene-specific primers. Expression 
levels were normalized using the hydroxymethylbilane synthase (HMBS) and beta-actin (ACTB) 
housekeeping genes. Primer sequences and PCR conditions can be provided on request. 
In all cases, real-time qRT-PCR assays were performed in triplicate on a LightCycler 480   
(Roche Applied Science), and expression levels were analyzed by the GeNorm software [56]. An 
unpaired, one-tailed t-test was performed to test for significant differences between the MS cohort and 
healthy controls. 
3.5. DNA Samples and Genotyping 
A total of 360 unrelated patients affected by clinically definite MS according to the revised 
McDonald’s criteria [57] and classified according to Lublin’s criteria [58] as having RR, SP, and PP 
courses, entered the study: they were consecutively selected from the patients referring to three MS 
Centers of Northern Italy. To avoid population stratification due to different genetic background, only 
patients of Caucasian origin coming from mainland Italy (Northern part of the peninsula) were 
included in the study. 
The female-to-male ratio was approximately 2:1 (236 females, 124 males); the mean age was   
46.4 ± 12 years (range 22–79 years); the mean age of onset was 30.4 ± 9.1 years (range 11–61 years); 
the mean disease duration was 15.6 ± 9.6 years (ranging from 0.5 to 55 years); the mean expanded 
disability status scale (EDSS) was 2.86 ± 2.43 (ranging from 0.5 to 9). As expected, the disease 
duration and the EDSS were significantly higher in the SP (83 patients) and PP (21 patients) groups 
compared to the RR (256 patients) group. 
As controls, 662 healthy volunteers were recruited. Among them, 360 were matched for age, gender, 
and geographic origin with the MS patients; the remaining 302 had the same female/male distribution 
of the patients, and an age above 52 years (mean age 57.9 years; range 52–79; SD ± 4.5). All control 
subjects had no sign of or familial history for neurological diseases. 
Genomic DNA extraction was performed from peripheral blood using either the salting-out procedure 
or an automated DNA extractor (Maxwell 16 System; Promega). DNA samples were quantified by using 
a PicoGreen assay (Invitrogen Life Technologies) and the microplate reader Wallac 1420 VICTOR
3 V 
(Perkin Elmer, Waltham, MA, USA). 
SNP genotyping was performed by HRM analysis. For each reaction, 7.5 ng of genomic DNA were 
amplified with a touch-down thermal profile in a final volume of 10 µL. Reactions were performed in 
384-well plates using the LightCycler 480 HRM Master Mix on a LightCycler 480 (Roche Applied 
Science). Amplicons were analyzed with the Gene Scanning Software (Roche Applied Science). 
Primer sequences, as well as the specific PCR conditions for each primer couple are available  
on request. 
3.6. Association Analysis 
SNP case-control analyses on allele and genotype frequency data were performed with χ² statistics 
(Fisher exact test) by using the PLINK software v.1.07 [59]. All analyzed SNPs had a minimal overall 
call rate of 95% and were tested for HWE in controls before inclusion in the analyses (PHWE > 0.05). Int. J. Mol. Sci. 2011, 12 8707 
 
 
The LD structure of the genomic region was determined from our SNP data using the Haploview 
v4.0 program [60]. Haplotype analysis (sliding-window option) and haplotype phasing were performed 
using the PLINK software. Only phased haplotypes with posterior probability of 1 were included for 
determining OR and 95% CI (risk haplotype vs all of the other alleles). All reported p values were not 
corrected for the number of comparisons. 
Power estimates indicated that, if each analyzed polymorphism (disease allele frequency of 15%) 
were to directly confer a 1.5-fold increase in the relative risk of MS, the case/control cohort used in 
this research would be of sufficient size to have 92% power to detect a significant association at the 
0.05 level. 
3.7. Web Resources 
The URLs for data presented in this work are as follows: 
  OMIM, Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/omim/ 
  The dChip software, http://www.dchip.org/ 
  The PLINK software, http://pngu.mgh.harvard.edu/~purcell/plink/ 
  The Haploview software, http://www.broad.mit.edu/mpg/haploview/ 
  The University of California Santa Cruz Genome Browser (UCSC), http://genome.ucsc.edu/ 
  The smiRNAdb repository, http://www.mirz.unibas.ch/cloningprofiles/ 
  The miRNA MAP website, http://mirnamap.mbc.nctu.edu.tw/ 
  The GeneCards website, http://www.genecards.org/ 
  The dbGaP database, http://www.ncbi.nlm.nih.gov/gap 
4. Limitations and Conclusions 
This study evidenced a significant up-regulation of mir-155 in PBMCs of RR MS patients by 
microbead-based expression profiling, which was subsequently confirmed by real-time RT-PCR 
experiments on both the mature mir-155 and its non-coding host gene BIC. Expression data are further 
strengthened by genetic studies, highlighting for the first time the existence of a risk haplotype 
mapping to the BIC/mir-155 locus. 
However, there are some caveats associated with the current study. First, the use of PBMCs instead 
of sorted T-cell subtypes might “dilute” cell-specific signatures, conceal opposite signals, and be 
influenced by differences in the relative cellular composition. On the other hand, PBMCs might 
represent a better option to identify biomarkers easily detectable in a diagnostic clinical setting. 
Secondly, our expression data require to be extended to larger homogeneous cohorts of RR patients in 
the remitting phase. Finally, although haplotype analysis evidenced a convincingly significant genetic 
association of mir-155 locus with MS, our study is underpowered to detect genetic associations with 
low-frequency variants and fosters future replications. 
In conclusion, the here presented results, together with those already reported in the literature, 
suggest that mir-155 can be considered as a potential easily-detectable peripheral biomarker and a 
promising therapeutic target in the treatment of MS, as well as in a variety of autoimmune disorders. Int. J. Mol. Sci. 2011, 12 8708 
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